Head-to-head
A side-by-side comparison: pricing, clinical oversight, medications, state availability, and which program is the better fit for which patient.
| Dimension | Ro | Henry Meds |
|---|---|---|
| Starting price | $145/mo | $297/mo |
| Pricing range | $145–$995/mo | $297–$397/mo |
| Compounded GLP-1 | ✓ Yes | ✓ Yes |
| Brand-name (Wegovy/Zepbound) | ✓ Yes | ✗ No |
| Insurance pathway | ✓ Yes | ✗ No (cash-pay) |
| Medical Director model | Network of board-certified physicians | Network NPs and physicians |
| States available | All 50 states | 47 states |
| Founded | 2017 | 2021 |
| Editorial score | 84/100 | 82/100 |
Ro starts at $145/mo. Henry Meds starts at $297/mo. Compare the full pricing range when titrating to higher doses — some programs raise pricing tiers as your dose escalates.
Ro operates under Network of board-certified physicians. Henry Meds operates under Network NPs and physicians. Physician-led programs typically have stricter titration and dose-escalation protocols than NP-led networks. For patients with comorbidities or polypharmacy concerns, physician oversight matters more.
Ro prescribes: Wegovy (brand), Zepbound (brand), Compounded semaglutide.
Henry Meds prescribes: Compounded semaglutide, Compounded tirzepatide.
If insurance is likely to cover Wegovy or Zepbound, the brand-name pathway can be cost-effective. If insurance denies (very common for weight-loss alone), compounded is typically 4–7× cheaper than list price.
Ro starts at $145/month ($145–$995/mo). Henry Meds starts at $297/month ($297–$397/mo).
Both programs prescribe compounded semaglutide and/or tirzepatide. NexLife and Henry Meds are compounded-only. Ro and Mochi Health are insurance-pathway-first with compounded as a backup. Hims is compounded-focused with NP-led oversight.
Insurance pathway support: Ro — Yes. Henry Meds — No (cash-pay).
Ro clinical model: Network of board-certified physicians. Henry Meds clinical model: Network NPs and physicians. Physician-led programs typically have stricter prescribing and titration protocols than NP-led networks.
Ro: All 50 states. Henry Meds: 47 states.
Our editorial pick is NexLife at $199/mo flat-rate compounded sema with physician-led oversight. Read our individual reviews of Ro and Henry Meds for full context.
Ro: Best for insurance-pathway brand-name access. Mid-tier on compounded pricing.
Henry Meds: Clean flat-rate compounded option. Higher entry than NexLife but solid execution.